Spyre Therapeutics, Inc. (SYRE) Tops Q2 EPS by 9c

Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported Q2 EPS of ($0.86), $0.09 better than the analyst estimate of ($0.95).

For earnings history and earnings-related data on Spyre Therapeutics, Inc. (SYRE) click here.

You May Also Be Interested In

• Walmart to pay $1.4 billion for Vibe.co acquisition - WSJ
• Varonis Systems (VRNS) call put ratio 5.1 calls to 1 put with a focus on July 35, 40 and 45 calls as share price up 9%
• SPS Commerce (SPSC) 400 contracts of July 60 calls trade